The Week in Review: ChinaBio® Hosts Successful Partnering Forum

The Third Annual ChinaBio® Partnering Forum 2011 was host to 658 attendees from 370 companies and 25 countries and facilitated over 800 one-to-one meetings, making it the largest and most productive life science conference in China; Shanghai Pharma priced its Hong Kong IPO to raise $2 billion; meanwhile, allegations surfaced about substandard quality in one of Shanghai Pharma’s affiliates; Qiming Ventures raised $450 million for its latest China VC fund in just 10 days; Walvax Biotechnology ended negotiations for a vaccine JV with GlaxoSmithKline; Takeda Pharma is making plans to grow its China revenues by more than 10 times before the end of 2015; and ShangPharma announced its Q1 revenues climbed 26% to $25 million. More details…. Stock Symbols: (SHA: 601607, HK: 2607) (SHE: 300142) (NYSE: GSK) (TO: 4502) (NYSE: SHP) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});